Lead the healthcare life sciences investment banking effort with a focus on biopharmaceuticals, medical technology, tools and diagnostics and pharma services.Team with other KPMG advisory functions/member firms to deliver full-service M&A solutions on a global basis.Sourced and executed 20+ transactions representing over $2 billion in value.Selected Transactions:- Myriad Genetics (EndoPredict Business) acquisition by EuroBio, sellside advisor- Clinres Farmacija acquisition by ProPharma, sell side advisor- Hitachi High-Tech strategic investment in Invivoscribe, buyside advisor- LI-COR Biosciences acquisition by Battery Ventures, sell side advisor- Toxikon acquisition by Labcorp, sellside advisor- LI-COR (phthalocyanine dyes) acquisition by Rakuten Medical, sellside advisor- Renal Services acquisition by DaVita, sellside advisor- R3 acquisition by 3Rivers Capital, sellside advisor- Fishawack Health acquisition by Bridgepoint, sellside advisor- Cybersonics (lithotripsy systems) acquisition by Olympus, buyside advisor- Biocomposites acquisition by TA Associates, sellside advisor- ImageStream Medical acquisition by Olympus, buyside advisor- EPL Archives acquisition by VWR, sellside advisor- Baxter (India infusion business) acquisition by Eurolife (Orbimed), sellside advisor- Sividon Diagnostics sale to Myriad Genetics, sellside advisor

Built successful advisory business by providing unbiased and differentiated advice to healthcare companies. Clients included publicly listed entities and portfolio companies of several private equity firms. Selected engagements:- Wrote a comprehensive business plan for a US consumer health company to leverage existing assets and core competencies to enter a new and fast growing market. Formulated customer value proposition, created detailed market and financial models and performed due diligence on relevant acquisition targets.- Counseled a European life sciences company on its sale process. Wrote marketing materials, established preliminary valuation range, identified buyer targets and initiated transaction discussions.- Advised a listed Chinese healthcare services company on potential US acquisitions. Refined search criteria based on transaction constraints and performed in-depth research on a short list of targets.

Participated in a concentrated and immersive program designed to prepare mid-career leaders for more senior roles in business.Researched, analyzed and generally explored two start-up opportunities in depth:- Service business focused on the accreditation of investors for general solicitations to ensure safe harbor status under Rule 506(c) of Regulation D of Section 4(a)(2) of the Securities Act of 1933.- Product business focused on a wireless charging solution for laptop computers, cell phone and other battery powered devices.Studied innovative approaches to value convertible bonds and long dated options.

Successfully restarted life sciences investment banking effort in a challenging market environment. Selected as point person for collaboration with Nomura Securities for Japan/US cross-border M&A.Sourced and executed 15+ transactions representing over $3 billion in value.Generated average annual revenue production of 123% of target with a book-run ratio of 84%.Selected transactions:- Sepracor acquisition (~$2.5 billion) by Dainippon Sumitomo Pharma, buyside advisor.- Sophion acquisition by Biolin Scientific, sellside advisor.- Corcept Therapeutics ~$50 million follow-on equity offering, lead book-runner.- Obagi Medical ~$60 million follow-on equity offering, lead book-runner.

Methodically built a leading biopharmaceutical investment banking franchise over a nine-year period. Through multiple market cycles, worked my way up from Associate to Managing Director.Sourced and executed 10+ transactions totaling over $1 billion in value.Revenue production (2007) was 185% of target with a book-run ratio of 66%.Selected transactions:- Incyte Pharmaceuticals ~$150 million convertible debt offering, lead book-runner.- Oscient Pharmaceuticals ~$225 million funded convertible exchange offering, lead book-runner.- Asthmatx ~$50 MM equity investment by Olympus, advisor.- Monogram Biosciences ~$30 MM convertible debt offering, lead book-runner.

Sourced and executed 30+ transactions representing over $3 billion in value.Revenue production (2006) was 222% of target (78% book-run ratio) and was #1 at the Principal level firm wide.

Led pitch assembly and transaction execution for ~$30 million (revenue) life sciences banking business under the supervision of three Managing Directors.Served as staffing manager for 3 years, managing the hiring and activities of team of ~10 associates/analysts.

Joined firm with 4-person team from prior firm to build out newly started life sciences banking effort.Gained substantial transaction experience over 18 months through the pitching/execution of 30+ transactions representing nearly $5 billion in value.

As part of a newly-hired management team, developed a strategic roadmap for a leading supplier of drug discovery instrumentation and consumables.Executed the acquisition of a privately held Norwegian instrumentation maker (Skatron Instruments).

Completed two-year analyst training program with rotations in technology M&A and healthcare industry groups.One of two analysts out of 15 to be promoted to Associate.

Coordinated company managed ~$40 million equity placement for a start-up molecular diagnostics company.Researched and edited private placement memorandum, established investor target directory, participated in investor presentations and prepared responses to due diligence inquiries.